Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (138)

2024

  1. A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24

    BJU International, Vol. 134, Núm. 4, pp. 568-577

  2. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression

    Frontiers in Immunology, Vol. 15

  3. Apparent Diffusion Coefficient as an Early Prognostic Factor of Response to Treatment with Androgen Deprivation Therapy and Radiotherapy in Patients with Prostate Cancer (Póster)

    International Journal of Radiation Oncology*Biology*Physics, Vol. 120, Núm. 2, pp. e527

  4. Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis

    International Journal of Molecular Sciences, Vol. 25, Núm. 18

  5. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Nature Genetics, Vol. 56, Núm. 9, pp. 1878-1889

  6. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

    Clinical Genitourinary Cancer, Vol. 22, Núm. 1, pp. 56-66

  7. Is trimodal therapy the current standard for muscle-invasive bladder cancer?

    Actas Urologicas Espanolas, Vol. 48, Núm. 5, pp. 345-355

  8. Total Neoadjuvant Therapy Approach for the Treatment of Locally Advanced Rectal Cancer: Where Do We Stand?

    Oncology (Switzerland), Vol. 102, Núm. 7, pp. 646-657

  9. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I)

    Revista de neurologia, Vol. 79, Núm. 1, pp. 21-29

  10. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II)

    Revista de neurologia, Vol. 79, Núm. 2, pp. 51-66

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  2. Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial

    Heart rhythm, Vol. 20, Núm. 6, pp. 822-830

  3. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

  4. Magnetic resonance in patients with cardiovascular devices. SEC-GT CRMTC/SEC-Heart Rhythm Association/SERAM/SEICAT consensus document

    Revista Espanola de Cardiologia, Vol. 76, Núm. 3, pp. 183-196

  5. Magnetic resonance in patients with cardiovascular devices. SEC-GT CRMTC/SEC-Heart Rhythm Association/SERAM/SEICAT consensus document

    Radiologia, Vol. 65, Núm. 3, pp. 269-284

  6. Medical help-seeking intentions among patients with early Alzheimer’s disease

    Frontiers in Psychiatry, Vol. 14

  7. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors in Locally Advanced Rectal Cancer

    Oncology (Switzerland), Vol. 101, Núm. 6, pp. 349-357

  8. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e93-e103

  9. PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?

    Clinical and Translational Imaging, Vol. 11, Núm. 3, pp. 241-254

  10. Prostate Cancer: Management of Biochemical Recurrence after Surgery

    Archivos espanoles de urologia, Vol. 76, Núm. 10, pp. 733-745